YOLFTbeta
41

TTY Biopharm Co Ltd

4105 · TWO · Healthcare / Drug Manufacturers - Specialty & Generic

84.10TWD+0.40 (+0.48%)

Price History

Full chart

Market Stats

Previous Close83.70
Open84.00
Day Range83.40 – 84.50
52-Week Range71.60 – 87.00
Volume920.50K
Market Cap19.62B
P/E (TTM)11.34
Forward P/E16.16
EPS6.96
Dividend Yield5.70%
Beta0.12
50-Day Avg77.45
200-Day Avg78.26

About

TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, Other Business Unit, and Re-investment Business Unit segments. It offers oncology drugs for the treatment of anticancer and adjunctive therapies under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Yondelis, Pemazyre, Pulmivex, Xpovio, Minjuvi, and Fustron names. The company also provides anti-infective drugs and anesthetics to treat second-line antimicrobial agents, influenza, and anesthetics under the Brosym, Bobimixyn, Colimycin, Cubicin, Lipo-AB, Flusine, Maxtam, Metacin, Flucelvax, Fluad, and Byfavo names; and healthcare products for the treatment of gastrointestinal health, bone health, and metabolic regulation under the Algitab, Alginos, Bio-Cal Plus, Sulfin names. In addition, it offers contract development and manufacturing (CDMO) services. The company was incorporated in 1960 and is headquartered in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Kuo-Chiang Chang
  • Employees0
  • HeadquartersNo.3-1, Park Street, Taipei, Taiwan, 11503, Taiwan
  • Websitehttps://www.tty.com.tw

Leadership

  • Mr. Kuo-Chiang ChangChief Financial Officer
  • Ms. Shu-Wen WangAccounting Officer
  • Ms. Shu-Fen HuangChief Legal & Compliance Officer
  • Wei-Ying YinDirector of Public Affairs Department
  • Mr. Jen-Yang ChangChief Human Resource Officer
  • Ms. Si-Yuan YangSenior Vice President
  • Mr. Allen ChuHead of Intensive Care Business Unit
  • Ms. Ching-Lan HouGeneral Manager
  • Yung-Min ChiangChief Auditor

Financials

Income Statement

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue4.08B4.04B4.47B4.22B4.54B5.06B5.51B5.89B6.45B
Growth (%)--1.04%+10.66%-5.47%+7.43%+11.60%+8.77%+7.05%+9.49%
Cost of Revenue1.41B1.37B1.56B1.62B1.77B2.04B2.22B2.48B2.73B
Gross Profit2.67B2.66B2.91B2.60B2.77B3.02B3.29B3.41B3.72B
Gross Margin65.49%66.00%65.09%61.70%61.03%59.69%59.70%57.94%57.66%
Operating Expense1.41B1.61B1.68B1.39B1.65B1.59B1.84B2.02B2.02B
Operating Income1.26B1.05B1.22B1.21B1.11B1.43B1.44B1.39B1.70B
Operating Margin30.82%26.11%27.39%28.70%24.54%28.19%26.23%23.65%26.42%
EBITDA1.76B1.83B1.37B1.37B1.28B1.61B1.65B2.13B2.36B
EBITDA Margin43.19%45.36%30.67%32.42%28.23%31.87%29.88%36.08%36.58%
Net Income1.34B1.46B900.08M924.18M831.89M1.09B1.13B1.45B1.56B
Net Income Margin32.97%36.21%20.15%21.89%18.34%21.62%20.50%24.60%24.16%
R&D295.68M361.06M298.55M261.60M287.60M353.44M310.44M271.39M194.35M
R&D as % of Total Revenue7.25%8.95%6.68%6.20%6.34%6.98%5.64%4.60%3.01%
Interest Expense017.29M14.81M19.41M18.98M23.15M35.36M38.74M38.66M
Interest Expense % of Total Revenue0.00%0.43%0.33%0.46%0.42%0.46%0.64%0.66%0.60%

Balance Sheet

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets9.51B9.05B9.55B9.36B9.30B9.60B9.87B10.86B11.35B
Total Liabilities3.40B2.66B3.38B3.28B3.53B3.37B3.37B3.35B3.30B
Total Equity5.50B5.80B5.57B5.45B5.17B5.66B5.94B6.75B7.24B
Cash1.44B2.37B2.42B2.22B2.22B2.36B2.62B2.77B2.52B
Total Debt---2.15B2.20B1.87B1.92B--
Net Debt818.49M---74.20M-20.11M-488.94M-705.98M--

Cash Flow

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow996.52M1.07B1.21B526.35M1.26B1.24B1.09B1.35B1.76B
Investing Cash Flow-730.07M1.70B-273.15M147.24M-168.78M-133.14M---
Financing Cash Flow-875.58M-1.86B-849.27M-806.61M-1.04B-1.10B-816.33M--
Capital Expenditure96.79M74.09M69.86M181.86M74.15M135.50M99.58M134.29M150.83M
Free Cash Flow899.03M987.49M1.14B344.49M1.18B1.10B985.73M1.22B1.61B
Dividends Paid944.87M1.12B1.12B994.60M994.60M745.95M845.41M870.27M1.04B
FCF to OCF90.22%91.96%94.16%65.45%94.10%89.03%90.82%90.05%91.44%
Dividend Paid to FCF105.10%113.31%98.22%288.72%84.13%67.80%85.76%71.62%64.82%

Earnings

Report DateAug 21, 2007Apr 29, 2008Oct 29, 2008Apr 28, 2009Aug 30, 2009Dec 2, 2009Mar 3, 2010Apr 15, 2010Jul 15, 2010Nov 1, 2010Mar 2, 2011Apr 29, 2011Aug 31, 2011Oct 31, 2011Feb 29, 2012May 30, 2012Jul 15, 2012Nov 28, 2012Mar 27, 2013May 29, 2013Aug 15, 2013Nov 12, 2013Feb 26, 2014May 14, 2014Aug 13, 2014Nov 14, 2014Feb 25, 2015May 14, 2015Aug 14, 2015Nov 11, 2015Mar 31, 2016May 9, 2016Aug 15, 2016Nov 11, 2016Jan 16, 2017May 3, 2017Aug 14, 2017Nov 13, 2017Mar 29, 2018Apr 12, 2018Aug 13, 2018Nov 14, 2018Mar 26, 2019Apr 11, 2019Aug 11, 2019Nov 13, 2019Mar 15, 2020May 13, 2020Aug 2, 2020Nov 3, 2020Mar 29, 2021May 5, 2021Aug 5, 2021Nov 3, 2021Mar 8, 2022May 13, 2022Aug 5, 2022Nov 4, 2022Mar 14, 2023May 10, 2023Aug 9, 2023Nov 3, 2023Mar 8, 2024May 9, 2024Sep 16, 2024Dec 18, 2024Feb 25, 2025May 13, 2025Aug 4, 2025Nov 7, 2025May 6, 2026Aug 5, 2026
EPS Estimate0.250.210.260.290.29--0.300.400.41-0.41-1.19--0.69-0.46--0.10-0.210.220.46-0.210.400.731.610.801.331.071.651.121.571.162.421.331.651.570.980.930.881.621.311.141.140.820.690.840.900.991.240.871.091.121.161.021.211.611.291.031.271.81-1.361.081.411.361.57
EPS Actual0.240.410.310.260.520.360.230.430.60-0.160.140.341.000.190.240.530.450.020.542.060.22-0.030.100.200.110.392.440.400.740.972.761.131.430.851.380.890.981.122.421.031.991.381.471.181.041.270.121.020.750.891.050.820.131.021.380.911.141.360.980.961.241.510.821.131.051.502.141.571.142.331.001.63
Surprise-4.00%95.24%19.23%-10.34%79.31%--43.33%50.00%-139.02%--17.07%--84.03%---34.78%-17.39%---130.00%--4.76%-50.00%-15.22%-90.48%85.00%32.88%71.43%41.25%7.52%-20.56%-16.36%-20.54%-37.58%-3.45%0.00%-22.56%20.61%-12.10%50.00%26.88%18.18%-21.60%-90.84%-10.53%-34.21%8.54%52.17%-2.38%-85.56%3.03%11.29%4.60%4.59%21.43%-15.52%-5.88%2.48%-6.21%-36.43%9.71%-17.32%-17.13%-15.44%5.56%65.25%-26.47%3.82%
TimingPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hours--After-hoursAfter-hoursAfter-hours-After-hours-After-hours--After-hours-After-hours--Pre-market-After-hoursPre-marketPre-market-Pre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-market

Key Statistics & Ratios

Market Cap19.62B
Enterprise Value18.26B
Trailing P/E11.34
Forward P/E16.16
Price / Sales2.95
Price / Book2.81
EPS6.96
Book Value27.97
Revenue (TTM)6.65B
Gross Profit (TTM)3.83B
EBITDA2.06B
Profit Margin26.04%
Operating Margin29.49%
Return on Equity25.11%
Return on Assets10.35%
Shares Outstanding248.65M
Shares Float191.67M
Beta0.12
Dividend Yield5.70%
Dividend Rate4.50
Payout Ratio90.73%

Dividends

20261×
4.50Mar 26, 2026
20251×
4.20Mar 27, 2025
20241×
3.50Mar 28, 2024
20231×
3.40Mar 30, 2023
20221×
3.00Jul 19, 2022
20211×
4.00Sep 14, 2021
20201×
4.00Jul 17, 2020
20191×
4.50Jul 12, 2019
20181×
4.50Jul 6, 2018
20171×
3.80Jul 10, 2017
20161×
3.50Jul 21, 2016
20151×
2.50Jul 6, 2015
20141×
1.76Aug 13, 2014
20131×
1.20Aug 20, 2013
20121×
0.21Aug 13, 2012
20111×
0.18Jul 29, 2011
20101×
0.99Aug 12, 2010
20091×
0.55Jul 31, 2009
20081×
0.55Aug 20, 2008

Stock Splits

  • Aug 13, 20141067:1000
  • Aug 20, 20131.089:1
  • Aug 13, 20121.24:1
  • Jul 29, 20111.234:1
  • Sep 20, 20101.09:1
  • Jul 31, 2009117:100
  • Aug 20, 2008118:100